Merus BV
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $23.88
- Today's High:
- $24.625
- Open Price:
- $23.9
- 52W Low:
- $12.03
- 52W High:
- $27.7
- Prev. Close:
- $23.95
- Volume:
- 324852
Company Statistics
- Market Cap.:
- $1.38 billion
- Book Value:
- 5.163
- Revenue TTM:
- $41.22 million
- Operating Margin TTM:
- -418.45%
- Gross Profit TTM:
- $-107838000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -26.67%
- Return on Equity TTM:
- -61.08%
Company Profile
Merus BV had its IPO on 2016-05-19 under the ticker symbol MRUS.
The company operates in the Healthcare sector and Biotechnology industry. Merus BV has a staff strength of 164 employees.
Stock update
Shares of Merus BV opened at $23.9 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $23.88 - $24.63, and closed at $24.39.
This is a +1.84% increase from the previous day's closing price.
A total volume of 324,852 shares were traded at the close of the day’s session.
In the last one week, shares of Merus BV have increased by +5.04%.
Merus BV's Key Ratios
Merus BV has a market cap of $1.38 billion, indicating a price to book ratio of 2.1479 and a price to sales ratio of 13.1869.
In the last 12-months Merus BV’s revenue was $41.22 million with a gross profit of $-107838000 and an EBITDA of $-170620000. The EBITDA ratio measures Merus BV's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Merus BV’s operating margin was -418.45% while its return on assets stood at -26.67% with a return of equity of -61.08%.
In Q2, Merus BV’s quarterly earnings growth was a positive 0% while revenue growth was a negative 17.4%.
Merus BV’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-3.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Merus BV’s profitability.
Merus BV stock is trading at a EV to sales ratio of 6.6505 and a EV to EBITDA ratio of -2.3717. Its price to sales ratio in the trailing 12-months stood at 13.1869.
Merus BV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $363.62 million
- Total Liabilities
- $65.85 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $349000
- Dividend Payout Ratio
- 0%
Merus BV ended 2024 with $363.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $363.62 million while shareholder equity stood at $257.41 million.
Merus BV ended 2024 with $0 in deferred long-term liabilities, $65.85 million in other current liabilities, 5099000.00 in common stock, $-669896000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $101.10 million and cash and short-term investments were $265.05 million. The company’s total short-term debt was $1,610,000 while long-term debt stood at $0.
Merus BV’s total current assets stands at $283.13 million while long-term investments were $46.50 million and short-term investments were $163.95 million. Its net receivables were $3.81 million compared to accounts payable of $7.60 million and inventory worth $12.22 million.
In 2024, Merus BV's operating cash flow was $0 while its capital expenditure stood at $349000.
Comparatively, Merus BV paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $24.39
- 52-Week High
- $27.7
- 52-Week Low
- $12.03
- Analyst Target Price
- $46.44
Merus BV stock is currently trading at $24.39 per share. It touched a 52-week high of $27.7 and a 52-week low of $27.7. Analysts tracking the stock have a 12-month average target price of $46.44.
Its 50-day moving average was $24.27 and 200-day moving average was $20.13 The short ratio stood at 18.34 indicating a short percent outstanding of 0%.
Around 840.5% of the company’s stock are held by insiders while 8385.9% are held by institutions.
Frequently Asked Questions About Merus BV
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.